In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
All content for Market Access Matters is the property of Access Infinity and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
Sharing your market access story and demonstrating value with Biogen’s Adrian Harrington
Market Access Matters
23 minutes
1 year ago
Sharing your market access story and demonstrating value with Biogen’s Adrian Harrington
Adrian Harrington, Senior Director Value and Access at Biogen, joins the podcast to discuss market access excellence – what it means to him, and the critical role visual communication is playing for market access leaders. Adrian also shares his views on what’s next for the market access function, detailing why leaders must embrace opportunities to demonstrate the value of market access and tell the story of their team’s success. Strong communication strategies are clearly important to Adrian ...
Market Access Matters
In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
